People with Graves' disease who still have thyroid-stimulating antibodies in their blood when they stop taking medication are more likely to have their hyperthyroidism return within 10 years.
Claim Context
In patients with Graves' disease treated with antithyroid drugs, persistent positivity of thyroid-stimulating immunoglobulins (TBII) at the end of treatment is associated with a significantly increased risk of hyperthyroidism relapse within 10 years.
“sólo la positividad de los TBII al final del tratamiento influyó de forma muy significativa (p < 0,05).”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review would determine whether TBII positivity consistently predicts relapse across diverse populations and assay methods, and quantify its sensitivity and specificity for relapse risk.
A systematic review and meta-analysis of all prospective studies measuring TBII levels at treatment end in Graves' disease patients, reporting relapse rates at 1, 3, 5, and 10 years, using standardized assays and adjusting for treatment duration and goiter size, with pooled likelihood ratios and ROC analysis.
An RCT could test whether suppressing TBII during treatment improves remission rates, establishing whether TBII is a modifiable target for preventing relapse.
A multicenter double-blind RCT of 400 adults with Graves' disease and TBII >2.0 IU/L at treatment end, randomized to continue antithyroid drugs for 12 additional months versus immediate discontinuation, with primary outcome of sustained remission at 5 years defined as euthyroidism without medication and TBII <1.0 IU/L.
A prospective cohort study could quantify the independent predictive value of TBII levels at treatment end after adjusting for goiter size and other confounders.
A prospective cohort of 800 adults with Graves' disease, measuring TBII levels at diagnosis, 6 months, 12 months, and at drug discontinuation, with annual thyroid function testing for 10 years, using multivariable Cox regression to determine hazard ratios for relapse per 1 IU/L increase in TBII.
A case-control study could compare TBII levels between patients who relapsed and those who remained in remission to assess whether elevated levels are consistently linked to recurrence.
A matched case-control study of 200 patients: 100 with relapse within 3 years of drug withdrawal and 100 matched controls (age, sex, treatment duration) who remained euthyroid, comparing peak and end-treatment TBII levels using ELISA, adjusting for goiter volume and smoking status.
A cross-sectional study could estimate the prevalence of elevated TBII among patients with established relapse, but cannot determine if it preceded the relapse.
A cross-sectional survey of 400 patients with Graves' disease relapse, measuring current TBII levels and comparing them to a control group of 400 patients in sustained remission, using the same assay method.